Trial Profile
Apatinib Mesylas combine with Xiaoyan Tang of advanced gastrointestinal cancer patients in an open and exploratory research
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Apr 2016 New trial record